Come up with a name for your new list and we'll add to it:
Flexus Biosciences raised a round of funding on October 30, 2013. Investors include
Kleiner Perkins Caufield & Byers.
Flexus is a biotechnology company focused on the discovery, development, and commercialization of small-molecule cancer immunotherapies targeting regulatory T cells. The company is leveraging unexploi…